Long-term follow-up of chemoimmunotherapy with rituximab, oxaliplatin, cytosine arabinoside, dexamethasone (ROAD) in patients with relapsed CD20+ B-cell non-Hodgkin lymphoma: Results of a study of the Mayo Clinic Cancer Center Research Consortium (MCCRC) MC0485 now known as academic and community cancer research united (ACCRU). - Witzig TE; Johnston PB; LaPlant BR; Kurtin PJ; Pederson LD; Moore DF Jr; Nabbout NH; Nikcevich DA; Rowland KM; Grothey A (American journal of hematology, 2017)